Skip to main content
Equibles
BRTX logo

BRTX · BioRestorative Therapies, Inc.

Track BRTX — free Ask ALVIS about BRTX
$0.25 -0.02 (-7.31%) At close · Jul 29
Going-concern doubt — flagged May 14, 2026

Substantial doubt about the company's ability to continue as a going concern.

“Based on these conditions, we believe we do not have sufficient cash for at least twelve months after the issuance date of the financial statements included in this Quarterly Report which raises substantial doubt about our ability to continue as a going concern.”
View the 10-Q filed May 14, 2026
Market Cap
$6.79M
Shares
25.48M

BioRestorative Therapies, Inc. Earnings Call Transcripts

Every quarterly earnings call for BioRestorative Therapies, Inc. (BRTX) — the full transcript with speaker labels, the audio replay, AI call highlights and a management-tone score, plus the matching 8-K earnings release and the quarter's 10-Q or 10-K. Investor days and conferences appear here too.

Revenue & result across quarters

Revenue Net income YoY up YoY down artefacts
▲11.8% $35,000 −$2.22M '24 Q1 24-03-31 ▲38.1% $89,100 −$4.03M '24 Q2 24-08-06 ▲660.9% $233,600 −$1.09M '24 Q3 24-11-13 ▲124.4% $43,300 −$1.64M '24 Q4 25-03-27 ▼28.6% $25,000 −$5.34M '25 Q1 25-05-14 ▲240.4% $303,300 −$2.66M '25 Q2 25-08-12 LATEST ▼94.9% $11,800 −$3.04M '25 Q3 25-11-12
Earnings call
FY25 · Q3
2025-11-12
BioRestorative Therapies, Inc. Q3 FY2025 Earnings Call
Positive tone BRTX-100 Phase II enrollment and clinical progress Biocosmeceuticals commercial business and Cartessa FDA regulatory strategy and Fast Track designation
Revenue
$11,800
▼ 94.9% YoY
Diluted EPS
$-0.33
Gross margin
10.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
BioRestorative Therapies, Inc. Q2 FY2025 Earnings Call
Confident tone BRTX-100 Phase II trial enrollment and data FDA regulatory pathway and Type B meeting ThermoStem metabolic program and licensing
Revenue
$303,300
▲ 240.4% YoY
Diluted EPS
$-0.30
Gross margin
97.1%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY25 · Q1
2025-05-14
BioRestorative Therapies, Inc. Q1 FY2025 Earnings Call
Confident tone BRTX-100 Phase II cLDD trial ThermoStem metabolic program Clinical data and presentations
Revenue
$25,000
▼ 28.6% YoY
Diluted EPS
$-0.64
Gross margin
88.4%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q4
2025-03-27
BioRestorative Therapies, Inc. Q4 FY2024 Earnings Call
Revenue
$43,300*
▲ 124.4% YoY
Gross margin
92.3%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-K
Earnings call
FY24 · Q3
2024-11-13
BioRestorative Therapies, Inc. Q3 FY2024 Earnings Call
Confident tone Efficacy endpoints (VAS, ODI, RMDQ) Indication expansion to cervical ThermoStem brown fat program
Revenue
$233,600
▲ 660.9% YoY
Diluted EPS
$-0.13
▼ 133.3% YoY
Gross margin
92.2%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q2
2024-08-06
BioRestorative Therapies, Inc. Q2 FY2024 Earnings Call
Confident tone ThermoStem metabolic/obesity program and GLP-1 comparison Cartessa commercial agreement and BioCosmeceutical revenue BRTX-100 Phase 2 clinical study and enrollment
Revenue
$89,100
▲ 38.1% YoY
Diluted EPS
$-0.50
Gross margin
92.7%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Earnings call
FY24 · Q1
2024-03-31
BioRestorative Therapies, Inc. Q1 FY2024 Earnings Call
Confident tone ThermoStem Metabolic Program BRTX-100 Phase 2 Clinical Trial Intellectual Property and Partnerships
Revenue
$35,000
▲ 11.8% YoY
Diluted EPS
$-0.33
Gross margin
100.0%
Rev · 8q Trailing quarterly revenue
Audio Transcript Slides 8-K10-Q
Showing 1–7 of 7 earnings calls
Key facts CIK 1505497 CUSIP 090655606 13F (30d) 3 filings 3 filers Visit website Investor relations

Report a Problem

Category
Description
Email (optional, for follow-up)